Nasdaq · Healthcare

AMARIN CORP PLC\UK (AMRN)

As-reported financials and recent SEC filings for AMARIN CORP PLC\UK, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$213.6M

Net income

$-38.8M

Net margin

-18.2%

Diluted EPS

$-0.09

ROE

-8.4%

P/E (TTM)

—

Market cap

$333.6M

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$213.6M	$228.6M	$306.9M	$369.2M	$583.2M
Gross profit	—	—	—	—	$461.9M
Operating income	$-50.2M	$-91.8M	$-67.6M	$-105.9M	$10.5M
Net income	$-38.8M	$-82.2M	$-59.1M	$-105.8M	$7.7M
Diluted EPS	$-0.09	$-0.20	$-0.15	$-0.26	$0.02

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

8-K2026-05-15

10-Q2026-04-29

8-K2026-04-29

42026-04-22

42026-04-21

42026-04-21

42026-04-21

42026-04-21

Go deeper on AMRN

Search AMARIN CORP PLC\UK’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.